Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18606890 | ANTI-CANCER COMPOSITION CONTAINING GOLD AND CYTOTOXIC AGENT | March 2024 | August 2024 | Allow | 5 | 0 | 1 | No | No |
| 18606917 | CYTOTOXICITY ASSAY COMPOSITION AND GOLD (III) COMPLEX | March 2024 | August 2024 | Allow | 5 | 0 | 1 | No | No |
| 18606361 | LIQUID PHARMACEUTICAL COMPOSITION OF GOLD | March 2024 | August 2024 | Allow | 5 | 0 | 1 | No | No |
| 18606260 | SOLID PHARMACEUTICAL GOLD-BASED COMPOSITION | March 2024 | July 2024 | Allow | 5 | 0 | 1 | No | No |
| 18534330 | ELECTRONICALLY WEAKLY COUPLED 4,4'-DIVINYLAZOBENZENE-BRIDGED DIRUTHENIUM COMPLEX BEARING TWO Ru(CO)Cl (PiPr3)2 MOIETIES AS AN INORGANIC CATALYST | December 2023 | February 2024 | Allow | 2 | 0 | 0 | No | No |
| 18382696 | 1-(4-NITROBENZYLIDENEAMINO)-5-PHENYLIMIDAZOLIDINE-2,4-DIONE AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 1 | No | No |
| 18484395 | 2-ALKOXY[4,3:6,4-TERPYRIDINE]-3-CARBONITRILES AS ANTIMICROBIAL COMPOUNDS | October 2023 | January 2024 | Allow | 4 | 0 | 1 | No | No |
| 18459778 | USE OF TAPINAROF FOR THE TREATMENT OF ATOPIC DERMATITIS | September 2023 | February 2024 | Allow | 5 | 1 | 1 | No | No |
| 18132241 | POLYMORPHS OF SELINEXOR | April 2023 | July 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18131273 | POLYMORPHS OF SELINEXOR | April 2023 | July 2023 | Allow | 3 | 1 | 0 | No | No |
| 18069886 | METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASE | December 2022 | June 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18085467 | NEUTROPHIL SUPPRESSION AS PRECONDITIONING TO INCREASE ONCOLYTIC BACTERIAL THERAPY | December 2022 | July 2024 | Allow | 18 | 1 | 1 | No | No |
| 18057505 | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | November 2022 | May 2024 | Allow | 17 | 1 | 1 | No | No |
| 17938531 | METHODS OF USING PROTEIN PALMITOYLATIONS INHIBITORS | October 2022 | July 2024 | Allow | 21 | 1 | 1 | No | No |
| 17944963 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | September 2022 | May 2024 | Abandon | 20 | 0 | 1 | No | No |
| 17896558 | SYSTEM AND ASSAY FOR MONITORING PRODUCTION/RELEASE OF MEMBRANE-LYTIC TOXINS IN BACTERIA AND COMPOUNDS FOR MODULATING SAME | August 2022 | April 2024 | Allow | 20 | 1 | 1 | No | No |
| 17820667 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | August 2022 | April 2024 | Allow | 20 | 1 | 0 | No | No |
| 17886075 | C4-CARBOXYLIC ACID-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | August 2022 | March 2024 | Allow | 20 | 1 | 1 | No | No |
| 17882046 | NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS | August 2022 | November 2022 | Allow | 3 | 0 | 1 | Yes | No |
| 17871178 | DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERS | July 2022 | April 2024 | Abandon | 21 | 1 | 0 | No | No |
| 17871663 | USE OF TAPINAROF FOR THE TREATMENT OF CHRONIC PLAQUE PSORIASIS | July 2022 | January 2023 | Allow | 6 | 2 | 0 | No | No |
| 17861809 | BIARYLMETHYL HETEROCYCLES | July 2022 | January 2024 | Allow | 18 | 0 | 1 | No | No |
| 17860884 | TOPICAL TREATMENT OF VITILIGO BY A JAK INHIBITOR | July 2022 | December 2022 | Allow | 6 | 1 | 0 | No | No |
| 17857478 | THERAMUTEIN MODULATORS | July 2022 | November 2023 | Allow | 16 | 1 | 0 | No | No |
| 17857492 | THERAMUTEIN MODULATORS | July 2022 | July 2023 | Allow | 13 | 0 | 0 | No | No |
| 17854443 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CHRONIC LUNG ALLOGRAFT DYSFUNCTION | June 2022 | September 2023 | Allow | 15 | 1 | 0 | No | No |
| 17789874 | High Triplet Yield Phenothiazine Donor-Acceptor Complexes For Photoredox Catalysis | June 2022 | November 2023 | Allow | 16 | 0 | 1 | Yes | No |
| 17849784 | CAMSYLATE SALTS OF TRIAZOLOPYRAZINE DERIVATIVES | June 2022 | December 2023 | Allow | 18 | 1 | 1 | No | No |
| 17789474 | METHOD FOR PREPARING DIAZOXIDE | June 2022 | January 2024 | Allow | 19 | 1 | 1 | No | No |
| 17843587 | METHOD OF CONTROLLING BLOOD SUGAR LEVEL AND TREATMENT OF DIABETES AND RELATED CONDITIONS | June 2022 | March 2024 | Abandon | 21 | 1 | 1 | No | No |
| 17836444 | COMBINATION MCL-1 INHIBITORS WITH ANTI-CANCER AGENTS | June 2022 | October 2023 | Allow | 16 | 1 | 1 | No | No |
| 17830682 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENT | June 2022 | October 2023 | Allow | 16 | 1 | 1 | No | No |
| 17831049 | Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases | June 2022 | December 2023 | Allow | 18 | 0 | 1 | No | No |
| 17804897 | METHOD FOR CONTROLLING FUSARIUM OXYSPORUM F. SP. CUBENSE TROPICAL RACE 4 | June 2022 | October 2023 | Allow | 16 | 1 | 0 | Yes | No |
| 17828983 | COMPOSITION AND METHOD FOR TREATING A DRUG-RESISTANT CANCER | May 2022 | December 2023 | Allow | 19 | 1 | 1 | No | No |
| 17826061 | COMPOUNDS FOR THE TREATMENT OF SARS | May 2022 | October 2023 | Allow | 17 | 1 | 1 | No | No |
| 17825019 | ALKYL-TERMINATED THIOCARBAMATE COMPLEX AND METHOD FOR TREATING CANCER | May 2022 | February 2024 | Allow | 21 | 1 | 1 | No | No |
| 17825009 | ALKYL AMINE DITHIOCARBAMATE GOLD COMPLEX FOR CANCER TREATMENT | May 2022 | February 2024 | Allow | 21 | 1 | 1 | No | No |
| 17751226 | KINASE MUTATION-ASSOCIATED NEURODEGENERATIVE DISORDERS | May 2022 | December 2023 | Allow | 23 | 1 | 0 | No | No |
| 17747754 | THERAPEUTIC COMPOUNDS AND USES THEREOF | May 2022 | February 2024 | Abandon | 21 | 0 | 1 | No | No |
| 17745924 | NOVEL SUBSTITUTED TETRAHYDROISOQUINOLINES AS ANTI-MITOTIC DRUG IN TRIPLE NEGATIVE BREAST CANCER | May 2022 | October 2023 | Allow | 17 | 2 | 0 | No | No |
| 17745045 | METHOD FOR TREATING CANCER USING A BCL-2 INHIBITOR IN CONJUNCTION WITH AN ALPHA-EMITTING RADIOIMMUNOTHERAPEUTIC | May 2022 | October 2023 | Allow | 17 | 1 | 1 | No | No |
| 17741162 | COMPOSITION OF PHYTONUTRIENTS FOR DIABETES MANAGEMENT | May 2022 | May 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17734345 | COMBINATION THERAPY | May 2022 | February 2024 | Abandon | 21 | 1 | 0 | No | No |
| 17723598 | METHODS OF REDUCING THE RISK OF HEART FAILURE | April 2022 | December 2023 | Allow | 20 | 1 | 1 | No | No |
| 17716156 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | April 2022 | March 2024 | Allow | 23 | 1 | 1 | No | No |
| 17699693 | METHOD OF PROMOTING ANTITUMOR OR ANTI-CANCER IMMUNITY | March 2022 | February 2024 | Allow | 23 | 1 | 1 | Yes | No |
| 17697448 | COMPOSITIONS AND METHODS FOR TREATING LUNG INJURIES ASSOCIATED WITH SARS-COV-2 INFECTIONS | March 2022 | August 2022 | Allow | 5 | 2 | 0 | No | No |
| 17694635 | COMPOSITIONS OF THIENOPYRIMIDINE DERIVATIVES | March 2022 | August 2023 | Allow | 17 | 0 | 0 | No | No |
| 17653982 | METHODS FOR TREATING OCULAR SURFACE PAIN | March 2022 | January 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17653256 | CARBOXYLIC ACID COMPOUNDS | March 2022 | April 2024 | Allow | 26 | 0 | 1 | No | No |
| 17681387 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | February 2022 | August 2023 | Allow | 18 | 0 | 1 | No | No |
| 17679113 | APPLICATIONS OF ELLAGIC ACID IN PREPARATION OF IMMUNOMODULATORY MEDICINES FOR TREATMENT OF NEUROMYELITIS OPTICA OR IMMUNE REJECTION AFTER SKIN TRANSPLANTATION | February 2022 | January 2024 | Allow | 22 | 1 | 1 | No | No |
| 17586515 | LIPID PRODRUGS OF MYCOPHENOLIC ACID AND USES THEREOF | January 2022 | August 2023 | Allow | 19 | 1 | 0 | No | No |
| 17576128 | CRYSTALLINE FORMS OF A DEOXYCYTIDINE KINASE INHIBITOR AND USES THEREOF | January 2022 | May 2022 | Allow | 4 | 1 | 1 | No | No |
| 17571352 | PPARy AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY | January 2022 | April 2023 | Allow | 15 | 0 | 0 | No | No |
| 17564446 | QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS | December 2021 | February 2024 | Abandon | 26 | 0 | 1 | No | No |
| 17554375 | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF | December 2021 | February 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17551105 | KIF18A INHIBITORS | December 2021 | March 2024 | Allow | 27 | 1 | 1 | No | No |
| 17527544 | PREPARATION METHOD OF SELENIUM-CONTAINING HETEROCYCLIC COMPOUNDS | November 2021 | October 2022 | Allow | 11 | 0 | 1 | No | No |
| 17520499 | Immunosuppressant Comprising TSAHC or a Pharmaceutically Acceptable Salts Thereof as an Active Ingredient | November 2021 | April 2024 | Allow | 29 | 1 | 0 | No | No |
| 17516542 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | November 2021 | June 2024 | Abandon | 31 | 1 | 1 | No | No |
| 17506497 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | October 2021 | April 2024 | Allow | 30 | 1 | 1 | No | No |
| 17501075 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | October 2021 | February 2024 | Allow | 28 | 1 | 1 | No | No |
| 17450254 | SYNTHETIC ROUTE TO SCOPOLAMINE AND/OR ATROPINE | October 2021 | April 2023 | Allow | 18 | 0 | 1 | No | No |
| 17494458 | RORGAMMA MODULATORS AND USES THEREOF | October 2021 | January 2024 | Allow | 27 | 1 | 1 | Yes | No |
| 17490778 | METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIES | September 2021 | April 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17478451 | HETEROCYCLIC COMPOUND AS SYK INHIBITOR AND/OR SYK-HDAC DUAL INHIBITOR | September 2021 | January 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17465087 | MODULATORS OF AIRWAY BASAL CELLS FOR THE TREATMENT OR PREVENTION OF LUNG DISEASES | September 2021 | April 2024 | Allow | 31 | 2 | 0 | No | No |
| 17462148 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | August 2021 | December 2023 | Allow | 27 | 1 | 1 | Yes | No |
| 17460775 | INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION | August 2021 | December 2021 | Allow | 4 | 1 | 0 | Yes | No |
| 17461695 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISEASE | August 2021 | November 2023 | Allow | 26 | 1 | 1 | No | No |
| 17459889 | Orally Administrated Therapeutic for Treating Mild Cognitive Impairment (MCI) and Improving Human Cognitive Function | August 2021 | October 2023 | Allow | 26 | 1 | 0 | No | No |
| 17404800 | Chlorin Derivatives or Pharmaceutically Acceptable Salts Thereof, Preparation Method and Use Thereof, and Combination Thereof with an Ultrasonic Medical System | August 2021 | February 2024 | Allow | 30 | 1 | 1 | No | No |
| 17398801 | Pharmaceutical Compositions Having Improved Storage Stability | August 2021 | December 2023 | Allow | 28 | 2 | 1 | No | No |
| 17396223 | ANTIMICROBIAL COMPOSITIONS AND RELATED METHODS | August 2021 | June 2024 | Allow | 34 | 1 | 1 | No | No |
| 17395723 | Compounds Useful in HIV Therapy | August 2021 | August 2023 | Allow | 24 | 1 | 0 | No | No |
| 17391081 | ANTIVIRAL AGENTS | August 2021 | March 2023 | Abandon | 19 | 0 | 1 | No | No |
| 17387888 | REAGENTS FOR QUANTITATIVE MASS SPECTROMETRY | July 2021 | January 2024 | Allow | 30 | 1 | 1 | No | No |
| 17443264 | NUCLEAR RECEPTOR MODULATORS | July 2021 | January 2024 | Abandon | 29 | 0 | 1 | No | No |
| 17380865 | Deuterium-Substituted 7-Substituted-2-(Benzylamino)-6-Ozopurine Compounds and Uses Thereof | July 2021 | March 2023 | Abandon | 19 | 0 | 1 | No | No |
| 17380943 | PTPN11 INHIBITORS | July 2021 | November 2023 | Allow | 28 | 1 | 1 | No | No |
| 17377885 | RET INHIBITOR FOR USE IN TREATING CANCER HAVING A RET ALTERATION | July 2021 | August 2023 | Allow | 25 | 1 | 0 | No | No |
| 17365656 | POLYMORPHS OF SELINEXOR | July 2021 | June 2023 | Allow | 23 | 1 | 0 | No | No |
| 17363534 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | June 2021 | July 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17364039 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | June 2021 | March 2023 | Abandon | 20 | 0 | 1 | No | No |
| 17356305 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | June 2021 | April 2023 | Allow | 21 | 0 | 1 | No | No |
| 17355792 | SYNTHESIS OF COELENTERAZINE SYNTHESIS INTERMEDIATE | June 2021 | July 2023 | Allow | 25 | 1 | 0 | Yes | No |
| 17354322 | CHEMICAL COMPOUNDS | June 2021 | June 2023 | Allow | 24 | 1 | 1 | No | No |
| 17349584 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | June 2021 | May 2023 | Allow | 23 | 1 | 0 | No | No |
| 17342873 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | June 2021 | January 2024 | Allow | 31 | 1 | 1 | No | No |
| 17341312 | ADMINISTRATION OF BERBERINE METABOLITES | June 2021 | December 2023 | Allow | 30 | 1 | 1 | Yes | No |
| 17337006 | COMBINATION THERAPY FOR TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | June 2021 | July 2023 | Allow | 26 | 1 | 0 | Yes | No |
| 17336444 | METALLOENZYME INHIBITOR COMPOUNDS | June 2021 | November 2023 | Allow | 29 | 1 | 1 | No | No |
| 17334166 | POLYMERIC METAL CHELATING COMPOSITIONS AND METHODS OF PREPARING SAME FOR CONTROLLING GROWTH AND ACTIVITIES OF LIVING CELLS AND ORGANISMS FOR THERAPEUTIC USE IN TREATING DISEASES IN ANIMALS, FISH OR HUMANS | May 2021 | December 2023 | Allow | 31 | 2 | 0 | No | No |
| 17325968 | COMPOSITIONS AND METHODS FOR TREATING LUNG INJURIES ASSOCIATED WITH SARS-COV-2 INFECTIONS | May 2021 | February 2022 | Allow | 9 | 2 | 0 | No | No |
| 17323482 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTEROPIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | May 2021 | July 2023 | Allow | 26 | 1 | 0 | No | No |
| 17318772 | CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT | May 2021 | October 2021 | Allow | 5 | 1 | 0 | No | No |
| 17318876 | CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT | May 2021 | October 2021 | Allow | 5 | 1 | 0 | No | No |
| 17318677 | CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT | May 2021 | October 2021 | Allow | 5 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WARD, PAUL V.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 38.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner WARD, PAUL V works in Art Unit 1624 and has examined 1,585 patent applications in our dataset. With an allowance rate of 75.5%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 22 months.
Examiner WARD, PAUL V's allowance rate of 75.5% places them in the 33% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by WARD, PAUL V receive 1.09 office actions before reaching final disposition. This places the examiner in the 16% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by WARD, PAUL V is 22 months. This places the examiner in the 79% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a -25.2% benefit to allowance rate for applications examined by WARD, PAUL V. This interview benefit is in the 0% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 44.1% of applications are subsequently allowed. This success rate is in the 95% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 75.9% of cases where such amendments are filed. This entry rate is in the 94% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 89.3% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 88.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 57.5% are granted (fully or in part). This grant rate is in the 74% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 2.0% of allowed cases (in the 77% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 25.7% of allowed cases (in the 94% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.